Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer

Author:

Tomita NaohiroORCID,Ishida Hideyuki,Tanakaya Kohji,Yamaguchi Tatsuro,Kumamoto Kensuke,Tanaka Toshiaki,Hinoi Takao,Miyakura Yasuyuki,Hasegawa Hirotoshi,Takayama Tetsuji,Ishikawa Hideki,Nakajima Takeshi,Chino Akiko,Shimodaira Hideki,Hirasawa Akira,Nakayama Yoshiko,Sekine Shigeki,Tamura Kazuo,Akagi Kiwamu,Kawasaki Yuko,Kobayashi Hirotoshi,Arai Masami,Itabashi Michio,Hashiguchi Yojiro,Sugihara Kenichi,Tomita Naohiro,Ishida Hideyuki,Tanakaya Koji,Yamaguchi Tatsuro,Kumamoto Kensuke,Tanaka Toshiaki,Hinoi Takao,Miyakura Yasuyuki,Hasegawa Hirotoshi,Ishikawa Hideki,Nakajima Takeshi,Chino Akiko,Sekine Shigeki,Tamura Kazuo,Akagi Kiwamu,Kobayashi Hirotoshi,Arai Masami,Itabashi Michio,Hashiguchi Yojiro,Sugihara Kenichi,

Abstract

AbstractHereditary colorectal cancer (HCRC) accounts for < 5% of all colorectal cancer cases. Some of the unique characteristics commonly encountered in HCRC cases include early age of onset, synchronous/metachronous cancer occurrence, and multiple cancers in other organs. These characteristics necessitate different management approaches, including diagnosis, treatment or surveillance, from sporadic colorectal cancer management. There are two representative HCRC, named familial adenomatous polyposis and Lynch syndrome. Other than these two HCRC syndromes, related disorders have also been reported. Several guidelines for hereditary disorders have already been published worldwide. In Japan, the first guideline for HCRC was prepared by the Japanese Society for Cancer of the Colon and Rectum (JSCCR), published in 2012 and revised in 2016. This revised version of the guideline was immediately translated into English and published in 2017. Since then, several new findings and novel disease concepts related to HCRC have been discovered. The currently diagnosed HCRC rate in daily clinical practice is relatively low; however, this is predicted to increase in the era of cancer genomic medicine, with the advancement of cancer multi-gene panel testing or whole genome testing, among others. Under these circumstances, the JSCCR guidelines 2020 for HCRC were prepared by consensus among members of the JSCCR HCRC Guideline Committee, based on a careful review of the evidence retrieved from literature searches, and considering the medical health insurance system and actual clinical practice settings in Japan. Herein, we present the English version of the JSCCR guidelines 2020 for HCRC.

Funder

JSCCR

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3